The Global Tubeless Insulin Pump Market was valued at USD 1.9 billion in 2024 and is estimated to grow at a CAGR of 20.6% to reach USD 12.2 billion by 2034.
According to the World Health Organization (WHO), diabetes is one of the leading causes of death globally, and the rising number of cases is creating an urgent need for more efficient and manageable treatment options. The traditional methods of insulin administration, such as daily injections, often lead to inconsistent results, reduced patient adherence, and discomfort.
Major players in the tubeless insulin pump market are Medtrum, MicroTech, Roche, TERUMO, Insulet, MannKind Corporation, and Pharmasens.
To strengthen their presence and market foothold in the tubeless insulin pump market, companies are focusing on several key strategies. First, they are heavily investing in research and development to integrate cutting-edge technologies such as continuous glucose monitoring (CGM), artificial intelligence (AI), and remote monitoring into their pumps, which provide enhanced control and ease of use for patients. Additionally, companies are forming strategic partnerships with healthcare providers and insurers to improve device accessibility and coverage for patients.
This product will be delivered within 2-4 business days.
According to the World Health Organization (WHO), diabetes is one of the leading causes of death globally, and the rising number of cases is creating an urgent need for more efficient and manageable treatment options. The traditional methods of insulin administration, such as daily injections, often lead to inconsistent results, reduced patient adherence, and discomfort.
Rising Demand for Continuous Glucose Monitoring (CGM) Integral Pumps
The continuous glucose monitoring (CGM) integral pumps segment held a significant share in 2024, driven by diabetes management that offers real-time data on glucose levels. CGM-integral pumps allow for seamless insulin delivery adjustments based on constant glucose monitoring, reducing the risk of hypo- or hyperglycemia. The combination of CGM and insulin delivery in one device ensures better control, precision, and convenience for users, especially for those with type 1 diabetes who require continuous monitoring.Bricks and Mortar to Gain Traction
The bricks and mortar segment generated significant revenues in 2024, driven by hospitals, clinics, and pharmacies, where tubeless insulin pumps are often sold, prescribed, and serviced. The focus is on the distribution and initial training of patients in proper pump usage. Companies in this segment are working to establish strong relationships with healthcare providers, offering comprehensive training and support services to ensure patients understand how to use their pumps effectively.Rising Adoption in Homecare
The homecare segment held a sizeable share in 2024, as patients seek more convenient, at-home diabetes management solutions. Tubeless insulin pumps in this sector offer flexibility, discretion, and ease of use, allowing patients to manage their insulin delivery at home. As healthcare systems move toward patient-centric care, companies are focusing on offering support services such as remote monitoring, telemedicine consultations, and patient education to ensure successful outcomes and better health management.Regional Insights
North America to Gain Traction
North America tubeless insulin pump market held a notable share in 2024, driven by the increasing prevalence of diabetes and the rising adoption of advanced diabetes management tools. A key driver in this market is the increasing preference for more convenient, less invasive insulin delivery systems, particularly among type 1 diabetes patients. With the availability of insurance coverage and growing awareness of the benefits of continuous insulin delivery, patients in North America are opting for tubeless insulin pumps that offer enhanced portability and functionality.Major players in the tubeless insulin pump market are Medtrum, MicroTech, Roche, TERUMO, Insulet, MannKind Corporation, and Pharmasens.
To strengthen their presence and market foothold in the tubeless insulin pump market, companies are focusing on several key strategies. First, they are heavily investing in research and development to integrate cutting-edge technologies such as continuous glucose monitoring (CGM), artificial intelligence (AI), and remote monitoring into their pumps, which provide enhanced control and ease of use for patients. Additionally, companies are forming strategic partnerships with healthcare providers and insurers to improve device accessibility and coverage for patients.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2024
Chapter 5 Market Estimates and Forecast, by Technology, 2021-2034 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Distribution Channel, 2021-2034 ($ Mn)
Chapter 7 Market Estimates and Forecast, by End Use, 2021-2034 ($ Mn)
Chapter 8 Market Estimates and Forecast, by Region, 2021-2034 ($ Mn)
Chapter 9 Company Profiles
Companies Mentioned
The key companies profiled in this Tubeless Insulin Pump market report include:- Insulet
- MannKind Corporation
- Medtrum
- MicroTech
- Pharmasens
- Roche
- TERUMO
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 130 |
| Published | September 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 1.9 Billion |
| Forecasted Market Value ( USD | $ 12.2 Billion |
| Compound Annual Growth Rate | 20.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 8 |
